36 results on '"Oroszi B"'
Search Results
2. Age-period-cohort analysis of mortality and its association with deprivation in Hungary, 2007-2021
- Author
-
Juhász, A, primary, Nagy, C, additional, Ádány, R, additional, Pikó, P, additional, Burkali, B, additional, and Oroszi, B, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary
- Author
-
Csanádi, M. (Marcell), Gini, A. (Andrea), Koning, H.J. (Harry) de, Széles, G. (György), Pitter, J.G. (János), Oroszi, B. (Beatrix), Pataki, P. (Piroska), Fadgyas-Freyler, P. (Petra), Korponai, G. (Gyulia), Vokó, Z. (Zoltán), Lansdorp-Vogelaar, I. (Iris), Csanádi, M. (Marcell), Gini, A. (Andrea), Koning, H.J. (Harry) de, Széles, G. (György), Pitter, J.G. (János), Oroszi, B. (Beatrix), Pataki, P. (Piroska), Fadgyas-Freyler, P. (Petra), Korponai, G. (Gyulia), Vokó, Z. (Zoltán), and Lansdorp-Vogelaar, I. (Iris)
- Abstract
Objective: The national population-based colorectal cancer screening programme in Hungary was initiated in December 2018. We aimed to evaluate the current programme and investigate the costs and benefits of potential future changes to overcome the low coverage of the target population. Methods: We performed an economic evaluation from a healthcare payer perspective using an established micro-simulation model (Microsimulation Screening Analysis-Colon). We simulated costs and benefits of screening with fecal immunochemical test in the Hungarian population aged 50–100, investigating also the impact of potential future scenarios which were assumed to increase invitation coverage: improvement of the IT platform currently used by GPs or distributing the tests through pharmacies instead of GPs. Results: The model predicted that the current screening programme could
- Published
- 2020
- Full Text
- View/download PDF
4. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season
- Author
-
Rondy, M., Gherasim, A., Casado, I., Launay, O., Rizzo, C., Pitigoi, D., Mickiene, A., Marbus, S. D., Machado, A., Syrjanen, R. K., Pem-Novose, I., Horvath, J. K., Larrauri, A., Castilla, J., Vanhems, P., Alfonsi, V., Ivanciuc, A. E., Kuliese, M., Van Gageldonk-Lafeber, R., Gomez, V., Ikonen, N., Lovric, Z., Ferenczi, A., Moren, A., Pozo, F., Garcia, M., Latorre, M., Omenaca, M., Oribe Amores, M., Munoz, N., Cilla, G., Fernandino, L., Martinez-Baz, I., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Bella, A., Appelgren, E. C., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Mihai, M. E., Cherciu, C. M., Dinu, S., Tecu, C., Nitescu, M., Bacruban, R., Azamfire, D., Dumitrescu, A., Ianosik, E., Ceausu, E., Popescu, C. P., Florescu, S. A., Tardei, G., Bejan, C., Teodor, A., Juganariu, G., Plesca, C., Duca, E., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Agostini, C., Ray, M., Merle, C., Foulongne, V., Lina, B., Laine, F., De Guibert, S., Lagathu, G., Tattevin, P., Jouneau, S., Esvant, A., Le Gallou, T., Carrat, F., Mawuvi, G., Chau, F., Nohynek, H., Haveri, A., Gefenaite, G., Velyvyte, D., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Bagdonas, A., Nunes, B., Kislaya, I., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Bernard, K., Kurecic-Filipovic, S., Visekruna Vucina, V., Topic, A., Papic, N., Budimir, J., Oroszi, B., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., EpiConcept [Paris], Institute of Health 'Carlos III', CIBER de Epidemiología y Salud Pública (CIBERESP), IDISNA, Pamplona, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Istituto Superiore di Sanità (ISS), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Lithuanian University of health Sciences, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Health and Welfare [Helsinki], Croatian Institute of Public Health [Zagreb] (CIPH), Office of the Chief Medical Officer, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire des pathogènes émergents -- Emerging Pathogens Laboratory (LPE-Fondation Mérieux), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute of Biology Bucharest of Romanian Academy, Epidemiology Department, Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Istituto Superiore di Sanità Rome, Rome, Italy, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), EpiConcept, Unión Europea, CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), F-CRIN, I-REIVAC, Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Center for Epidemiology Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], 'Carol Davila' University of Medicine and Pharmacy, National Institute for Public Health and the Environment [Bilthoven] ( RIVM ), Instituto Nacional de Saúde Doutor Ricardo Jorge, Croatian Institute of Public Health, Zagreb, Hospices Civils de Lyon ( HCL ), Centre International de Recherche en Infectiologie ( CIRI ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon ), Istituto Superiore de Sanita, HAL-UPMC, Gestionnaire, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,0301 basic medicine ,Pediatrics ,Epidemiology ,Efetividade da Vacina Antigripal ,A(H3N2) ,Influenza ,cases control ,elderly ,hospitalisation ,vaccine effectiveness ,Elderly ,0302 clinical medicine ,vaccine ,Outcome Assessment, Health Care ,Influenza A Virus ,Hospitalisation ,awareness ,030212 general & internal medicine ,media_common ,Vaccine effectiveness ,virus diseases ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,Middle Aged ,Hospitals ,3. Good health ,Hospitalization ,Influenza Vaccines ,H3N2 Subtype ,Female ,Seasons ,influenza ,Rapid Communication ,Human ,Adult ,medicine.medical_specialty ,Adolescent ,Influenza vaccine ,030106 microbiology ,Outcome Assessment (Health Care) ,03 medical and health sciences ,[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology ,Virology ,Influenza, Human ,medicine ,Aged ,European Union ,Humans ,Influenza A Virus, H3N2 Subtype ,media_common.cataloged_instance ,Vacina Antigripal ,European union ,Cases control ,Cases Control ,business.industry ,Public health ,Cuidados de Saúde ,Public Health, Environmental and Occupational Health ,Case-control study ,Influenza a ,Confidence interval ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Emergency medicine ,[ SDV.IMM.VAC ] Life Sciences [q-bio]/Immunology/Vaccinology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,Prevention control ,business - Abstract
Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal). In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate. Funding: The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). info:eu-repo/semantics/publishedVersion
- Published
- 2017
5. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza
- Author
-
Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barbera, J., Gefenaite, G., Larrauri, A., Rizzo, C., Pitigoi, D., Syrjanen, R. K., Machado, A., Filipovic, S. K., Horvath, J. K., Paradowska-Stankiewicz, I., Marbus, S., Moren, A., Valenciano, M., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Ray, M., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Casado, I., Diaz-Gonzalez, J., Guevara, M., Martinez-Baz, I., Fernandino, L., Navascues, A., Ezpeleta, C., Chamorro, J., Barrado, L., Ortega, M. T., De Gaetano Donati, K., Cauda, R., Donato, C., Taccari, F., Campana, L., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., Alfonsi, V., Bella, A., Puzelli, S., Castrucci, M. R., Orsi, A., Ansaldi, F., Manini, I., Montomoli, E., Chironna, M., Germinario, C., Diez-Domingo, J., Sanudo, B., Carratala Munuera, C., Correcher Medina, P., Gil Guillen, V., Larrea Gonzalez, R., Limon Ramirez, R., Mico Esparza, J. L., Mollar Maseres, J., Otero Reigada, M. C., Tortajada Girbes, M., Schwarz Chavarri, G., Ambrozaitis, A., Jancoriene, L., Zablockiene, B., Zagminas, K., Aukse, M., Damuleviciene, G., Grimalauskaite, R., Kuliese, M., Lesauskaite, V., Velyvyte, D., Niesters, H., Stolk, R. P., Zagmines, K., Rahamat-Langendoen, J., Gherasim, A., Pozo, F., Altzibar, J., Arraras, J. G., Cilla, G., Marco, E., Vidal Garcia, M., Omenaca, M., Ivanciuc, A. E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Nohynek, H., Ikonen, N., Haveri, A., Gomez, V., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Visekruna Vucina, V., Kaic, B., Novosel, I. P., Petrovic, G., Ferenczi, A., Oroszi, B., Korczynska, M. R., Brydak, L. B., Cieslik-Tarkota, R., Rozwadowska, B., Skolimowska, G., Hulboj, D., Jakubik, A., Meijer, A., Van Gageldonk-Lafeber, A. B., Research Council of Lithuania, and European Union
- Subjects
0301 basic medicine ,Male ,Veterinary medicine ,Immunology and Microbiology (all) ,medicine.disease_cause ,Polymerase Chain Reaction ,Aged ,Aged, 80 and over ,Case-Control Studies ,Clinical Laboratory Techniques ,Europe ,Female ,Hospitalization ,Humans ,Influenza A Virus, H1N1 Subtype ,Influenza A Virus, H3N2 Subtype ,Influenza B virus ,Influenza Vaccines ,Influenza, Human ,Respiratory Tract Infections ,Seasons ,Sentinel Surveillance ,Vaccination ,Molecular Medicine ,Veterinary (all) ,Public Health, Environmental and Occupational Health ,Infectious Diseases ,Seasonal influenza ,IMOVE+ ,0302 clinical medicine ,80 and over ,Influenza A Virus ,Influenza A virus ,030212 general & internal medicine ,Respiratory tract infections ,virus diseases ,3. Good health ,H3N2 Subtype ,Public Health ,Human ,medicine.medical_specialty ,Influenza vaccine ,030106 microbiology ,Virus ,Hospital ,03 medical and health sciences ,Repeated Vaccination ,Internal medicine ,medicine ,H1N1 Subtype ,Influenza Vaccine Effectiveness ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Environmental and Occupational Health ,Cuidados de Saúde ,Case-control study ,Influenza ,Negative case ,influenza vaccination, test negative case control, vaccine effectiveness ,business - Abstract
In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study. info:eu-repo/semantics/publishedVersion
- Published
- 2017
6. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project
- Author
-
Rondy, Marc, Larrauri, A., Casado, I., Alfonsi, V., Pitigoi, D., Launay, O., Syrjänen, R. K., Gefenaite, G., Machado, A., Vučina, V. V., Horváth, J. K., Paradowska-Stankiewicz, I., Marbus, S. D., Gherasim, A., Díaz-González, J. A., Rizzo, C., Ivanciuc, A. E., Galtier, F., Ikonen, N., Mickiene, A., Gomez, V., Kurečić Filipović, S., Ferenczi, A., Korcinska, M. R., Van Gageldonk-Lafeber, R., Valenciano, M., Altzibar, Jone M., Arraras, Ion Garcia, Cilla, Gustavo, Marco, Elisa, Vidal, Matxalen, Omenaca, Manuel, Castilla, J., Navascues, A., Ezpeleta, C., Barrado, L., Ortega, M. T., Bella, A., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Orsi, A., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Lenzi, N., Lesieur, Z., Loulergue, P., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Nohynek, H., Haveri, A., Kuliese, M., Velyvyte, D., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Kaić, B., Oroszi, B., Brydak, L. B., Cieślak, K., Kowalczyk, D., Szymański, K., Jakubik, A., Skolimowska, G., Hulboj, D., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., Palmieri, Annapina, Giannitelli, Stefania, Ranghiasci, Alessia, Bacruban, Rodica, Azamfire, Delia, Dumitrescu, Aura, Ianosik, Elena, Duca, Elena, Bejan, Codrina, Teodor, Andra, Florescu, Simin-Aysel, Popescu, Corneliu, Tardei, Gratiela, Charpentier, Julien, Marin, Nathalie, Doumenc, Benoit, Le Jeunne, Claire, Krivine, Anne, Momcilovic, Sonia, Benet, Thomas, Amour, Selilah, Henaff, Laetitia, Jokinen, Jukka, Lyytikainen, Outi, Palmu, Arto, Siren, Paivi, Ruokokoski, Esa, Nunes, Baltazar, Rodrigues, Ana Paula, Guiomar, Raquel, Gomes, Victor, Quaresma, Filipa, Vale, Luis, Garcia, Teresa, Bernardo, Teresa, Dias, Liliana, Fonseca, Paula, Amorim, Helena, Rolo, Joao, Pacheco, Helena, Branquinho, Paula, Corte-Real, Rita, Pocas, Jose, Lopes, Paula, Peres, Maria Joao, Ribeiro, Rosa, Duarte, Paula, Pedroso, Ermelinda, Rodrigues, Sara, Silverio, Ana Rita, Pedreira, Diana Gomes, Fonseca, Marta Ferreira, Vince, Adriana, Topić, Antea, Papić, Neven, Mihalić, Jelena Budimir, Novosel, Iva Pem, Petrović, Goranka, Zajec, Martina, Draženović, Vladimir, Hercegh, Eva, Szalai, Balint, Antmann, Katalin, Nagy, Kamilla, Unión Europea, EpiConcept, Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Superiore de Sanita, University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute for Health and Welfare [Helsinki], and National Institute for Public Health and the Environment [Bilthoven] (RIVM)
- Subjects
Infecções Respiratórias ,0301 basic medicine ,Male ,Heart disease ,Epidemiology ,Efetividade da Vacina Antigripal ,0302 clinical medicine ,Influenza A Virus, H1N1 Subtype ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Outcome Assessment, Health Care ,80 and over ,Influenza A Virus ,Medicine ,030212 general & internal medicine ,Aged, 80 and over ,[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,Vaccination ,virus diseases ,3. Good health ,Europe ,Hospitalization ,Influenza Vaccines ,case control ,elderly ,hospitalisation ,influenza ,severe acute respiratory infection ,vaccine effectiveness ,vaccine-preventable diseases ,Vaccine-preventable diseases ,Female ,Public Health ,Seasons ,Research Article ,Human ,medicine.medical_specialty ,Influenza vaccine ,030106 microbiology ,Aged ,Humans ,Influenza B virus ,Influenza, Human ,Logistic Models ,Outcome Assessment (Health Care) ,Sentinel Surveillance ,Vaccine Potency ,Public Health, Environmental and Occupational Health ,Virology ,Hospital ,03 medical and health sciences ,Diabetes mellitus ,Internal medicine ,H1N1 Subtype ,Vacina Antigripal ,Intensive care medicine ,business.industry ,Environmental and Occupational Health ,Cuidados de Saúde ,Case-control study ,medicine.disease ,Influenza ,Confidence interval ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,business - Abstract
Members of the I-MOVE+ project - Portugal: Baltazar Nunes, Ana Paula Rodrigues, Raquel Guiomar (Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal), Victor Gomes, Filipa Quaresma, Luis Vale, Teresa Garcia, Teresa Bernardo, Liliana Dias, Paula Fonseca, Helena Amorim, João Rolo, Helena Pacheco, Paula Branquinho, Rita Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon, Portugal),José Poças, Paula Lopes, Maria João Peres, Rosa Ribeiro, Paula Duarte, Ermelinda Pedroso, Sara Rodrigues, Ana Rita Silvério, Diana Gomes Pedreira, Marta Ferreira Fonseca, (Centro Hospitalar de Setúbal, Setúbal, Portugal). We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases. The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. info:eu-repo/semantics/publishedVersion
- Published
- 2017
7. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study
- Author
-
Kissling, E, primary, Valenciano, M, additional, Larrauri, A, additional, Oroszi, B, additional, Cohen, J M, additional, Nunes, B, additional, Pitigoi, D, additional, Rizzo, C, additional, Rebolledo, J, additional, Paradowska-Stankiewicz, I, additional, Jiménez-Jorge, S, additional, Horváth, J K, additional, Daviaud, I, additional, Guiomar, R, additional, Necula, G, additional, Bella, A, additional, O’Donnell, J, additional, Głuchowska, M, additional, Ciancio, B C, additional, Nicoll, A, additional, and Moren, A, additional
- Published
- 2013
- Full Text
- View/download PDF
8. I-MOVE multicentre case--control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine efectiveness with increasing time since vaccination?
- Author
-
Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., Cohen, J. M., Oroszi, B., Rizzo, C., Machado, A., Pitigoi, D., Domegan, L., Paradowska-Stankiewicz, I., Buchholz, U., Gherasim, A., Daviaud, I., Horváth, J. K., Bella, A., Lupulescu, E., and O'Donnell, J.
- Published
- 2016
- Full Text
- View/download PDF
9. “I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9
- Author
-
Kissling, E, primary, Valenciano, M, additional, Falcão, J M, additional, Larrauri, A, additional, Widgren, K, additional, Pitigoi, D, additional, Oroszi, B, additional, Nunes, B, additional, Savulescu, C, additional, Mazick, A, additional, Lupulescu, E, additional, Ciancio, B, additional, and Moren, A, additional
- Published
- 2009
- Full Text
- View/download PDF
10. An efficient voice driven face animation method for cyber telepresence applications.
- Author
-
Feldhoffer, G. and Oroszi, B.
- Published
- 2009
- Full Text
- View/download PDF
11. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: Results from the I-MOVE multicentre case-control study, 2011/12
- Author
-
Kissling, E., Valenciano, M., Ciancio, B. C., Kramarz, P., Nicoll, A., Moren, A., Savulescu, C., Cohen, J. M., Mosnier, A., Daviaud, I., Bui, T. T., Oroszi, B., Horváth, J. K., Caini, S., Rózsa, M., Rebolledo, J., O’malley, A., O’donnell, J., Domegan, L., Moran, J., Coughlan, S., Joyce, M., Collins, C., Rizzo, C., Bella, A., Rota, M. C., Giannitelli, S., Simona Puzelli, Donatelli, I., Declich, S., Stankiewicz, I. P., Gluchowska, M., Brydak, L., Kosek, A. W., Grzeganek, D., Nunes, B., Machado, A., Batista, I., Guiomar, R., Pechirra, P., Gonçalves, P., Conde, P., Falcão, I., Pitigoi, D., Ivanciuc, A. E., Lupulescu, E., Jiménez-Jorge, S., Mateo, S., Pozo, F., Ledesma, J., Casas, I., and Larrauri, A.
12. I-MOVE: a European network to measure the effectiveness of influenza vaccines
- Author
-
Valenciano, M., Ciancio, Bc, I-Move, Study Team, Ciancio, B. C., Kramarz, P., Nicoll, A., Kissling, E., Moren, A., Savulescu, C., Seyler, T., Mazick, A., Widgren, K., Bui, T., Cohen, J. M., Daviaud, I., Mosnier, A., Oroszi, B., Caini, S., Csohan, A., Horvath, J. K., Rozsa, M., Barret, A. S., Domegan, L., O Donnell, J., Declich, S., Puzelli, S., Rizzo, C., Rota, M. C., Dieleman, J., Sturkenboom, M., Wijnans, L., Voordouw, B., Gluchowska, M., Paradowska-Stankiewicz, I., Stefanoff, P., Batista, I., Barreto, M., Conde, P., Falcao, J. M., Goncalves, P., Guiomar, R., Machado, A., Nunes, B., Pechirra, P., Helena Rebelo-de-Andrade, Santos, L., Falcao, I., Alexandrescu, V., Ivanciuc, A., Lupulescu, E., Pitigoi, D., Durnall, H., Fleming, D., Andrews, N., Hardelid, P., Kafatos, G., Pebody, R., Watson, J., Zambon, M., Kavanagh, K., Robertson, C., Mcmenamin, J., Reynolds, A., Larrauri, A., Jimenez-Jorge, S., Mateo, S., Pozo, F., Barricarte, A., Castilla, J., Garcia Cenoz, M., Martinez-Baz, I., and Guevara, M.
13. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case–control study
- Author
-
Kissling, E., Valenciano, M., Ciancio, B. C., Kramarz, P., Nicoll, A., Moren, A., Savulescu, C., Oroszi, B., Horváth, K. J., Csohán, Á, Saverio Caini, Rózsa, M., Barret, A. S., O’malley, A., O’donnell, J., Moran, J., Coughlan, S., Joyce, M., Collins, C., Rizzo, C., Bella, A., D’ancona, P., Giannitelli, S., Rota, M. C., Puzelli, S., Donatelli, I., Stankiewicz, I. P., Stefanoff, P., Gluchowska, M., Brydak, L., Romanowska, M., Nunes, B., Machado, A., Batista, I., Pechirra, P., Gonçalves, P., Conde, P., Falcão, I., Pitigoi, D., Baetel, A. E., Lupulescu, E., Jiménez-Jorge, S., Mateo, S., Pozo, F., Ledesma, J., Casas, I., and Larrauri, A.
14. Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
- Author
-
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, and Kissling E
- Published
- 2024
- Full Text
- View/download PDF
15. Discrepancies between the Spatial Distribution of Cancer Incidence and Mortality as an Indicator of Unmet Needs in Cancer Prevention and/or Treatment in Hungary.
- Author
-
Ádány R, Juhász A, Nagy C, Burkali B, Pikó P, McKee M, and Oroszi B
- Abstract
There is a rich body of literature on the distribution of cancer incidence and mortality in socioeconomically different world regions, but none of the studies has compared the spatial distribution of mortality and incidence to see if they are consistent with each other. All malignant neoplasms combined and cervical, colorectal, breast, pancreatic, lung, and oral cancers separately were studied in the Hungarian population aged 25-64 years for 2007-2018 at the municipality level by sex. In each case, the spatial distribution of incidence and mortality were compared with each other and with the level of deprivation using disease mapping, spatial regression, risk analysis, and spatial scan statistics. A positive association between deprivation and mortality was found for each type of cancer, but there was no significant association for male colorectal cancer (relative risk (RR) 1.00; 95% credible interval (CI) 0.99-1.02), pancreatic cancer (RR: 1.01; 95%CI 0.98-1.04), and female colorectal cancer incidence (RR: 1.01; 95%CI 0.99-1.03), whereas a negative association for breast cancer (RR: 0.98; 95%CI 0.96-0.99) was found. Disease mapping analyses showed only partial overlap between areas of high incidence and mortality, often independent of deprivation. Our results highlight not only the diverse relationship between cancer burden and deprivation, but also the inconsistent relationship between cancer incidence and mortality, pointing to areas with populations that require special public health attention.
- Published
- 2024
- Full Text
- View/download PDF
16. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
- Author
-
Antunes L, Mazagatos C, Martínez-Baz I, Naesens R, Borg ML, Petrović G, Fatukasi T, Jancoriene L, Machado A, Oroszi B, Husa P, Lazar M, Dürrwald R, Howard J, Melo A, Pérez-Gimeno G, Castilla J, Bernaert E, Džiugytė A, Makarić ZL, Fitzgerald M, Mickienė A, Gomez V, Túri G, Součková L, Marin A, Tolksdorf K, Nicolay N, and Rose AMC
- Subjects
- Humans, Aged, Europe epidemiology, Female, Male, Middle Aged, Adult, Case-Control Studies, Young Adult, Aged, 80 and over, Adolescent, Hospitalization statistics & numerical data, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology, Vaccine Efficacy statistics & numerical data, Vaccination statistics & numerical data
- Abstract
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
- Author
-
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, and Kissling E
- Subjects
- Humans, Europe epidemiology, Female, Male, Middle Aged, Adult, Case-Control Studies, Aged, Young Adult, Adolescent, Vaccination methods, Vaccination statistics & numerical data, Immunization Programs, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, Primary Health Care, Vaccine Efficacy
- Abstract
In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case-control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26-53 %) overall, 48 % (95 % CI: 31-61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3-49 %) at 6-14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Socioeconomic determinants and reasons for non-acceptance to vaccination recommendations during the 3 rd - 5 th waves of the COVID-19 pandemic in Hungary.
- Author
-
Ligeti AS, Oroszi B, Luca C, Bilics E, Ágoston J, Röst G, and Koltai J
- Subjects
- Humans, Hungary, Male, Female, Adult, Middle Aged, Young Adult, Adolescent, Aged, Surveys and Questionnaires, Pandemics prevention & control, Vaccination statistics & numerical data, Vaccination psychology, Patient Acceptance of Health Care statistics & numerical data, Patient Acceptance of Health Care psychology, COVID-19 prevention & control, COVID-19 epidemiology, Vaccination Hesitancy psychology, Vaccination Hesitancy statistics & numerical data, COVID-19 Vaccines administration & dosage, Socioeconomic Factors
- Abstract
Background: In Hungary, although six types of vaccines were widely available, the percentage of people receiving the primary series of COVID-19 vaccination remained below the EU average. This paper investigates the reasons for Hungary's lower vaccination coverage by exploring changing attitudes towards vaccination, socio-demographic determinants, and individual reasons for non-acceptance during the 3
rd - 5th pandemic waves of COVID-19., Methods: The study's empirical analysis is based on representative surveys conducted in Hungary between February 19, 2021, and June 30, 2022. The study used a total of 17 surveys, each with a sample size of at least 1000 respondents. Binomial logistic regression models were used to investigate which socio-demographic characteristics are most likely to influence vaccine hesitancy in Hungary. The study analysed 2506 open-ended responses to identify reasons for vaccine non-acceptance. The responses were categorised into four main categories and 13 sub-categories., Results: Between the third and fifth wave of the pandemic, attitudes towards COVID-19 vaccination have significantly changed. Although the proportion of vaccinated individuals has increased steadily, the percentage of individuals who reported not accepting the vaccine has remained almost unchanged. Socio-demographic characteristics were an important determinant of the observed vaccine hesitancy, although they remained relatively stable over time. Individuals in younger age groups and those with lower socioeconomic status were more likely to decline vaccination, while those living in the capital city were the least likely. A significant reason behind vaccine refusal can undoubtedly be identified as lack of trust (specifically distrust in science), facing an information barrier and the perception of low personal risk., Conclusion: Although compulsory childhood vaccination coverage is particularly high in Hungary, voluntary adult vaccines, such as the influenza and COVID-19 vaccines, are less well accepted. Vaccine acceptance is heavily affected by the social-demographic characteristics of people. Mistrust and hesitancy about COVID-19 vaccines, if not well managed, can easily affect people's opinion and acceptance of other vaccines as well. Identifying and understanding the complexity of how vaccine hesitancy evolved during the pandemic can help to understand and halt the decline in both COVID-19 and general vaccine confidence by developing targeted public health programs to address these issues., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
19. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
- Author
-
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, and Kissling E
- Subjects
- Humans, Aged, Female, Europe epidemiology, Male, Middle Aged, Case-Control Studies, Aged, 80 and over, Vaccination statistics & numerical data, European People, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines therapeutic use, Vaccine Efficacy, SARS-CoV-2 immunology, Seasons
- Abstract
Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns., Objective: To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used., Design, Setting, and Participants: This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden. Participants were primary care patients aged 60 years or older with acute respiratory infection symptoms who were recruited at the 11 sites after the start of the COVID-19 vaccination campaign from September 2022 to August 2023. Cases and controls were defined as patients with positive and negative, respectively, reverse transcription-polymerase chain reaction (RT-PCR) test results., Exposures: The exposure was COVID-19 vaccination. The exposure group consisted of patients who received a COVID-19 vaccine during the autumn and winter 2022 to 2023 vaccination campaign and 14 days or more before symptom onset. Reference group included patients who were not vaccinated during or in the 6 months before the 2022 to 2023 campaign (seasonal CVE), those who were never vaccinated (absolute CVE), and those who were vaccinated with at least the primary series 6 months or more before the campaign (relative CVE). For relative CVE of second boosters, patients receiving their second booster during the campaign were compared with those receiving 1 booster 6 months or more before the campaign., Main Outcomes and Measures: The outcome was RT-PCR-confirmed, medically attended, symptomatic SARS-CoV-2 infection. Four CVE estimates were generated: seasonal, absolute, relative, and relative of second boosters. CVE was estimated using logistic regression, adjusting for study site, symptom onset date, age, chronic condition, and sex., Results: A total of 9308 primary care patients were included, with 1687 cases (1035 females; median [IQR] age, 71 [65-79] years) and 7621 controls (4619 females [61%]; median [IQR] age, 71 [65-78] years). Within 14 to 89 days after vaccination, seasonal CVE was 29% (95% CI, 14%-42%), absolute CVE was 39% (95% CI, 6%-60%), relative CVE was 31% (95% CI, 15% to 44%), and relative CVE of second boosters was 34% (95% CI, 18%-47%) against all SARS-CoV-2 variants. In the same interval, seasonal CVE was 44% (95% CI, -10% to 75%), absolute CVE was 52% (95% CI, -23% to 82%), relative CVE was 47% (95% CI, -8% to 77%), and relative CVE of second boosters was 46% (95% CI, -13% to 77%) during a period of high XBB circulation. Estimates decreased with time since vaccination, with no protection from 180 days after vaccination., Conclusions and Relevance: In this case-control study among older Europeans, all CVE approaches suggested that COVID-19 vaccines administered in autumn and winter 2022 to 2023 offered at least 3 months of protection against symptomatic, medically attended, laboratory-confirmed SARS-CoV-2 infection. The effectiveness of new COVID-19 vaccines against emerging SARS-CoV-2 variants should be continually monitored using CVE seasonal approaches.
- Published
- 2024
- Full Text
- View/download PDF
20. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
- Author
-
Maurel M, Mazagatos C, Goerlitz L, Oroszi B, Hooiveld M, Machado A, Domegan L, Ilić M, Popescu R, Sève N, Martínez-Baz I, Larrauri A, Buda S, Túri G, Meijer A, Gomez V, O'Donnell J, Mlinarić I, Timnea O, Diez AO, Dürrwald R, Horváth JK, Dijkstra F, Rodrigues AP, McKenna A, Filipović SK, Lazar M, Kaczmarek M, Bacci S, and Kissling E
- Subjects
- Humans, Adolescent, Europe epidemiology, Adult, Middle Aged, Female, Aged, Male, Child, Preschool, Child, Young Adult, Case-Control Studies, Infant, Seasons, Infant, Newborn, Vaccination statistics & numerical data, Respiratory Tract Infections epidemiology, Respiratory Tract Infections diagnosis, Respiratory Tract Infections prevention & control, Influenza Vaccines immunology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Influenza, Human epidemiology, Influenza, Human diagnosis, Primary Health Care statistics & numerical data, Vaccine Efficacy
- Abstract
Background: Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates., Methods: We estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0-14, 15-64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one)., Results: We included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations., Discussion: Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022-2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants.
- Author
-
Horváth JK, Túri G, Krisztalovics K, Kristóf K, and Oroszi B
- Abstract
Hungary provides the opportunity to evaluate the effectiveness of COVID-19 vaccination in a setting where naturally acquired immunity and hybrid immunity are likely to play a greater role due to suboptimal vaccination coverage., Methods: A test-negative study was conducted during the 2022-2023 respiratory season at the primary care level to determine the effectiveness of at least one COVID-19 booster dose in preventing medically attended symptomatic RT-PCR-confirmed SARS-CoV-2 infection in adults. Unvaccinated patients were used as a reference group., Results: A total of 247 cases and 1073 controls were included in the analysis. CVE was 56.8% (95% CI: 11.9-78.8%) in the population aged 60 years and older and 2.3% (95% CI: -50.0-36.3%) in the younger adults against COVID-19 caused by Omicron subvariants, mainly BA.5, BQ.1, and XBB.1. Self-reported COVID-19 in the 60-365 days prior to the current illness did not confer protection against reinfection without vaccination, but together with booster vaccination, it reduced the risk of COVID-19 by 63.0% (95% CI: -28.0-89.3%) and 87.6% (95% CI: 26.4-97.9%) among the 18-59 and 60+ age groups, respectively., Conclusions: CVE against COVID-19 was moderately high in the 60+ age groups. Because of the benefit of hybrid immunity, persons with previous SARS-CoV-2 infection should still be considered for vaccination campaigns.
- Published
- 2024
- Full Text
- View/download PDF
22. Comparative analysis of health status and health service utilization patterns among rural and urban elderly populations in Hungary: a study on the challenges of unhealthy aging.
- Author
-
Kovacs N, Piko P, Juhasz A, Nagy C, Oroszi B, Ungvari Z, and Adany R
- Subjects
- Humans, Female, Aged, Male, Urban Population, Hungary epidemiology, Health Status, Patient Acceptance of Health Care, Health Services
- Abstract
The demographic transition poses a significant challenge for health systems, especially in Central and Eastern European (CEE) countries, where the healthcare needs of aging populations are on the rise. This study aimed to describe and compare the health status and utilization of health services among the elderly residing in urban and rural areas of the most deprived region in Hungary. A comprehensive health survey was conducted in 2022, involving a randomly selected sample of 443 older adults (≥ 65 years) in Northeast Hungary. Multivariable logistic regression models adjusting for age, sex, education, financial status, chronic diseases, and activity limitations were used to investigate the association between type of residence and health service use. Among the study participants, 62.3% were female, 38.3% attained primary education, 12.5% reported a bad or very bad financial situation and 52.6% lived in urban areas. Overall, 24% of the elderly rated their health as very good or good (27.8% in urban and 19.7% in rural areas), while 57.8% (52.6% and 63.5% in urban and rural areas) reported limitations in daily activities. Compared to urban residents, rural residents reported lower rates of dentist visits (p = 0.006), specialist visits (p = 0.028), faecal occult blood testing (p < 0.001), colorectal cancer screening with colonoscopy (p = 0.014), and breast cancer screening (p = 0.035), and a higher rate of blood pressure measurement (p = 0.042). Multivariable models indicated that urban residence was positively associated with faecal occult blood testing (OR = 2.32, p = 0.014), but negatively associated with blood pressure (OR = 0.42, p = 0.017) and blood glucose measurements (OR = 0.48, p = 0.009). These findings highlight the influence of residence on health service utilization among older adults in Hungary. Further comprehensive studies are needed to better understand the health needs of the elderly population and to develop policies aimed at promoting healthy aging in CEE countries., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
- Author
-
Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, and Kissling E
- Subjects
- Humans, Adolescent, Aged, COVID-19 Vaccines, SARS-CoV-2, BNT162 Vaccine, Vaccine Efficacy, Europe epidemiology, Primary Health Care, COVID-19 epidemiology, COVID-19 prevention & control, Influenza, Human epidemiology, Influenza, Human prevention & control
- Abstract
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases.MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.ResultsAmong adults, PS VE was 37% (95% CI: 24-47%) overall and 60% (95% CI: 44-72%), 43% (95% CI: 26-55%) and 29% (95% CI: 13-43%) < 90, 90-179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32-51%) overall and 56% (95% CI: 47-64%), 22% (95% CI: 2-38%) and 3% (95% CI: -78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.ConclusionPrimary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.
- Published
- 2024
- Full Text
- View/download PDF
24. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
- Author
-
Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, Sève N, McKenna A, Meijer A, Rodrigues AP, Martínez-Baz I, Mlinarić I, Latorre-Margalef N, Túri G, Lazăr M, Mazagatos C, Echeverria A, Abela S, Bourgeois M, Machado A, Dürrwald R, Petrović G, Oroszi B, Jancoriene L, Marin A, Husa P, Duffy R, Dijkstra F, Gallardo García V, Goerlitz L, Enouf V, Bennett C, Hooiveld M, Guiomar R, Trobajo-Sanmartín C, Višekruna Vučina V, Samuelsson Hagey T, Lameiras Azevedo AS, Castilla J, Xuereb G, Delaere B, Gómez V, Tolksdorf K, Bacci S, Nicolay N, Kaczmarek M, and Rose AM
- Subjects
- Humans, Influenza B virus, Influenza A Virus, H3N2 Subtype, Vaccination, Case-Control Studies, Seasons, Hospitals, Primary Health Care, Influenza Vaccines, Influenza, Human epidemiology, Influenza, Human prevention & control, Influenza A Virus, H1N1 Subtype
- Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
- Published
- 2024
- Full Text
- View/download PDF
25. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
- Author
-
Rose AMC, Pozo F, Martínez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, Petrović G, Loghin II, Vaikutyte R, Buda S, Machado A, Duffy R, Oroszi B, Howard J, Echeverria A, Andreu C, Barbezange C, Džiugytė A, Nonković D, Popescu CP, Majauskaite F, Tolksdorf K, Gomez V, Domegan L, Horváth JK, Castilla J, García M, Demuyser T, Borg ML, Tabain I, Lazar M, Kubiliute I, Dürrwald R, Guiomar R, O'Donnell J, Kristóf K, Nicolay N, Bacci S, and Kissling E
- Subjects
- Adult, Humans, Seasons, Influenza A Virus, H3N2 Subtype genetics, Case-Control Studies, Vaccine Efficacy, Europe epidemiology, Hospitalization, Hospitals, Vaccination, Influenza, Human epidemiology, Influenza, Human prevention & control, Influenza A Virus, H1N1 Subtype genetics, Influenza Vaccines, Pneumonia
- Abstract
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
26. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
- Author
-
Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Martínez-Baz I, Ilić M, Carnahan AS, Mihai ME, Martínez A, Goerlitz L, Enouf V, Horváth JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmartín C, Mlinarić I, Latorre-Margalef N, Ivanciuc A, Lopez A, Dürrwald R, Falchi A, Túri G, Meijer A, Melo A, O'Donnell J, Castilla J, Vučina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, and Kissling E
- Subjects
- Child, Humans, Europe epidemiology, Influenza A Virus, H3N2 Subtype genetics, Primary Health Care, Vaccine Efficacy, Infant, Newborn, Infant, Child, Preschool, Adolescent, Young Adult, Adult, Middle Aged, Influenza A virus, Influenza A Virus, H1N1 Subtype genetics, Influenza Vaccines, Influenza, Human epidemiology, Influenza, Human prevention & control
- Abstract
Background: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study., Materials and Methods: Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression., Results: We included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25-45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25-49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35-56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46-65) and 79% (95% CI: 64-88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70-81); overall, 84%, 72% and 71% were among 0-14-year-olds, 15-64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73-85) and 90% (95% CI: 85-94) without this mutation., Conclusion: The 2022-2023 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2)., Competing Interests: None., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
27. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
- Author
-
Antunes L, Mazagatos C, Martínez-Baz I, Gomez V, Borg ML, Petrović G, Duffy R, Dufrasne FE, Dürrwald R, Lazar M, Jancoriene L, Oroszi B, Husa P, Howard J, Melo A, Pozo F, Pérez-Gimeno G, Castilla J, Machado A, Džiugytė A, Karabuva S, Fitzgerald M, Fierens S, Tolksdorf K, Popovici SO, Mickienė A, Túri G, Součková L, Nicolay N, and Rose AM
- Subjects
- Humans, Case-Control Studies, SARS-CoV-2 genetics, Hospitalization, Europe epidemiology, RNA, Messenger, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
- Published
- 2024
- Full Text
- View/download PDF
28. Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method.
- Author
-
Horváth JK, Ferenci T, Ferenczi A, Túri G, Röst G, and Oroszi B
- Abstract
Several studies have reported the waning effectiveness of COVID-19 vaccines. This study aims to demonstrate the applicability of the screening method for estimating vaccine effectiveness (VE) in a pandemic. We report VE in Hungary, estimated with the screening method, in 2021, covering a period of Alpha and the Delta variant, including the booster dose roll-out. Hungary is in a unique position to use six different vaccines in the same population. All vaccines provided a high level of protection initially, which declined over time. While the picture is different in each age group, the waning of immunity is apparent for all vaccines, especially in the younger age groups and the Sinopharm, Sputnik-V, and AstraZeneca vaccines, which performed similarly. This is clearly reversed by booster doses, more prominent for those three vaccines, where the decline in protection is more evident. Overall, two vaccines, Pfizer/BioNTech and Moderna, tend to produce the best results in all age groups, even with waning immunity considered. Using the screening method in future pandemic waves is worthwhile, especially in countries struggling with a lack of resources or when there is a need to deliver VE results within a short timeframe due to urgent decision-making.
- Published
- 2022
- Full Text
- View/download PDF
29. Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary.
- Author
-
Oroszi B, Juhász A, Nagy C, Horváth JK, Komlós KE, Túri G, McKee M, and Ádány R
- Abstract
Governments are increasingly looking to vaccination to provide a path out of the COVID-19 pandemic. Hungary offers an example to investigate whether social inequalities compromise what a successful vaccine program can achieve. COVID-19 morbidity, mortality, and vaccination coverage were characterized by calculation of indirectly standardized ratios in the Hungarian population during the third pandemic wave at the level of municipalities, classified into deprivation quintiles. Then, their association with socioeconomic deprivation was assessed using ecological regression. Compared to the national average, people living in the most deprived municipalities had a 15-24% lower relative incidence of confirmed COVID-19 cases, but a 17-37% higher relative mortality and a 38% lower vaccination coverage. At an ecological level, COVID-19 mortality showed a strong positive association with deprivation and an inverse association with vaccination coverage (RR
Vaccination = 0.86 (0.75-0.98)), but the latter became non-significant after adjustment for deprivation (RRVaccination = 0.95 (0.84-1.09), RRDeprivation = 1.10 (1.07-1.14)). Even what is widely viewed as one of the more successful vaccine roll outs was unable to close the gap in COVID-19 mortality during the third pandemic wave in Hungary. This is likely to be due to the challenges of reaching those living in the most deprived municipalities who experienced the highest mortality rates during the third wave.- Published
- 2022
- Full Text
- View/download PDF
30. Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary.
- Author
-
Csanádi M, Gini A, Koning H, Széles G, Pitter JG, Oroszi B, Pataki P, Fadgyas-Freyler P, Korponai G, Vokó Z, and Lansdorp-Vogelaar I
- Subjects
- Colonoscopy, Cost-Benefit Analysis, Humans, Hungary, Mass Screening, Occult Blood, Colorectal Neoplasms diagnosis, Early Detection of Cancer
- Abstract
Objective: The national population-based colorectal cancer screening programme in Hungary was initiated in December 2018. We aimed to evaluate the current programme and investigate the costs and benefits of potential future changes to overcome the low coverage of the target population., Methods: We performed an economic evaluation from a healthcare payer perspective using an established micro-simulation model (Microsimulation Screening Analysis-Colon). We simulated costs and benefits of screening with fecal immunochemical test in the Hungarian population aged 50-100, investigating also the impact of potential future scenarios which were assumed to increase invitation coverage: improvement of the IT platform currently used by GPs or distributing the tests through pharmacies instead of GPs., Results: The model predicted that the current screening programme could lead to 6.2% colorectal cancer mortality reduction between 2018 and 2050 compared to no screening. Even higher reductions, up to 16.6%, were estimated when tests were distributed through pharmacies and higher coverage was assumed. This change in the programme was estimated to require up to 26 million performed fecal immunochemical tests and 1 million colonoscopies for the simulated period. These future scenarios have acceptable cost-benefit ratios of €8000-€8700 per life-years gained depending on the assumed adherence of invited individuals., Conclusions: With its limitations, the current colorectal cancer screening programme in Hungary will have a modest impact on colorectal cancer mortality. Significant improvements in mortality reduction could be made at acceptable costs, if the tests were to be distributed by pharmacies allowing the entire target population to be invited.
- Published
- 2021
- Full Text
- View/download PDF
31. Unequal burden of COVID-19 in Hungary: a geographical and socioeconomic analysis of the second wave of the pandemic.
- Author
-
Oroszi B, Juhász A, Nagy C, Horváth JK, McKee M, and Ádány R
- Subjects
- Bayes Theorem, Female, Humans, Hungary epidemiology, Male, Pandemics, Risk Factors, SARS-CoV-2, Socioeconomic Factors, COVID-19
- Abstract
Introduction: We describe COVID-19 morbidity, mortality, case fatality and excess death in a country-wide study of municipalities in Hungary, exploring the association with socioeconomic status., Methods: The spatial distribution of morbidity, mortality and case fatality was mapped using hierarchical Bayesian smoothed indirectly standardised ratios. Indirectly standardised ratios were used to evaluate the association between deprivation and the outcome measures. We looked separately at morbidity and mortality in the 10 districts with the highest and 10 districts with the lowest share of Roma population., Results: Compared with the national average, the relative incidence of cases was 30%-36% lower in the most deprived quintile but the relative mortality and case fatality were 27%-32% higher. Expressed as incidence ratios relative to the national average, the most deprived municipalities had a relative incidence ratio of 0.64 (CI: 0.62 to 0.65) and 0.70 (CI: 0.69 to 0.72) for males and females, respectively. The corresponding figures for mortality were 1.32 (CI: 1.20 to 1.44) for males and 1.27 (CI: 1.16 to 1.39) for females and for case fatality 1.27 (CI: 1.16 to 1.39) and 1.32 (CI: 1.20 to 1.44) for males and females, respectively. The excess death rate (per 100 000) increased with deprivation levels (least deprived: 114.12 (CI: 108.60 to 119.84) and most deprived: 158.07 (CI: 149.30 to 167.23)). The 10 districts where Roma formed the greatest share of the population had an excess mortality rate 17.46% higher than the average for the most deprived quintile., Conclusions: Those living in more deprived municipalities had a lower risk of being identified as a confirmed COVID-19 case but had a higher risk of death. An inverse association between trends in morbidity and mortality by socioeconomic conditions should be a cause for concern and points to the need for responses, including those involving vaccination, to pay particular attention to inequalities and their causes., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
32. Early Phase of the COVID-19 Outbreak in Hungary and Post-Lockdown Scenarios.
- Author
-
Röst G, Bartha FA, Bogya N, Boldog P, Dénes A, Ferenci T, Horváth KJ, Juhász A, Nagy C, Tekeli T, Vizi Z, and Oroszi B
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, COVID-19, Child, Child, Preschool, Coronavirus Infections mortality, Coronavirus Infections prevention & control, Coronavirus Infections transmission, Female, Humans, Hungary epidemiology, Infant, Infant, Newborn, Male, Middle Aged, Models, Statistical, Pandemics prevention & control, Pneumonia, Viral mortality, Pneumonia, Viral prevention & control, Pneumonia, Viral transmission, Quarantine, Risk Factors, SARS-CoV-2, Sex Factors, Young Adult, Betacoronavirus, Coronavirus Infections epidemiology, Disease Outbreaks prevention & control, Pneumonia, Viral epidemiology
- Abstract
COVID-19 epidemic has been suppressed in Hungary due to timely non-pharmaceutical interventions, prompting a considerable reduction in the number of contacts and transmission of the virus. This strategy was effective in preventing epidemic growth and reducing the incidence of COVID-19 to low levels. In this report, we present the first epidemiological and statistical analysis of the early phase of the COVID-19 outbreak in Hungary. Then, we establish an age-structured compartmental model to explore alternative post-lockdown scenarios. We incorporate various factors, such as age-specific measures, seasonal effects, and spatial heterogeneity to project the possible peak size and disease burden of a COVID-19 epidemic wave after the current measures are relaxed.
- Published
- 2020
- Full Text
- View/download PDF
33. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
- Author
-
Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, Cohen JM, Oroszi B, Rizzo C, Machado A, Pitigoi D, Domegan L, Paradowska-Stankiewicz I, Buchholz U, Gherasim A, Daviaud I, Horváth JK, Bella A, Lupulescu E, O Donnell J, Korczyńska M, and Moren A
- Subjects
- Case-Control Studies, Disease Outbreaks prevention & control, Europe epidemiology, Female, Humans, Influenza, Human virology, Male, Prevalence, Risk Factors, Treatment Outcome, Disease Outbreaks statistics & numerical data, Influenza Vaccines therapeutic use, Influenza, Human epidemiology, Influenza, Human prevention & control, Seasons, Vaccination statistics & numerical data
- Abstract
Since the 2008/9 influenza season, the I-MOVE multicentre case-control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0-65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1-15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9-67.9) and remained between this value and 50.3% (95% CI: 34.8-62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3-82.4) 44 days after vaccination to 21.4% (95% CI: -57.4-60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
- Published
- 2016
- Full Text
- View/download PDF
34. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
- Author
-
Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, Horvath JK, O'Donnell J, Bella A, Guiomar R, Lupulescu E, Savulescu C, Ciancio BC, Kramarz P, and Moren A
- Subjects
- Adult, Aged, Case-Control Studies, Child, Child, Preschool, Europe epidemiology, Female, Humans, Infant, Influenza, Human epidemiology, Influenza, Human virology, Logistic Models, Male, Middle Aged, Odds Ratio, Outcome Assessment, Health Care, Pandemics prevention & control, Sentinel Surveillance, Young Adult, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human prevention & control
- Abstract
Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1)., Methods and Findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9)., Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.
- Published
- 2011
- Full Text
- View/download PDF
35. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.
- Author
-
Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, and Moren A
- Subjects
- Adolescent, Adult, Case-Control Studies, Child, Child, Preschool, Europe, Female, Humans, Infant, Infant, Newborn, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H1N1 Subtype pathogenicity, Male, Middle Aged, Seasons, Species Specificity, Time Factors, Young Adult, Influenza Vaccines immunology, Influenza, Human prevention & control, Models, Statistical
- Abstract
Background: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza., Methods: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination., Results: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B., Conclusions: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.
- Published
- 2011
- Full Text
- View/download PDF
36. Health risk factors and mortality in Pécs City, Hungary in the 1990s.
- Author
-
Morava E, Végh E, Bóna I, Kiss I, Oroszi B, and Józan P
- Subjects
- Adolescent, Adult, Aged, Cause of Death, Female, Health Behavior, Humans, Hungary epidemiology, Life Style, Male, Middle Aged, Population Surveillance, Prevalence, Risk Factors, Urban Health trends, Health Status Indicators, Mortality trends
- Abstract
In the period of 1990-1994 an increase of all causes mortality for 35-74 years old males was observed both in Pécs and in all Hungary. From 1994 to 1997 the mortality decreased. Similar changes, but of smaller dimension, were observed in the female population. The increasing mortality of the early 1990s is attributed primarily to the extra psycho-social stress of this period. The data of the population survey at Pécs in 1995-96 were compared to the data of earlier surveys. The mean blood total cholesterol levels and the prevalence of smoking decreased from 1990 to 1996. The prevalence of hypertension and male obesity increased. Physical inactivity, unhealthy diet and lack of improvement of diet still represent significant health problems. High prevalence of increased gamma-glutamyl transferase indicate high prevalence of excess alcohol consumption. The risk factor profile of 18-25 year old males is very unfavourable. Smoking prevalence in females aged 26-35 years exceeds that of males of the same age group. Preventive efforts should be focused to young males and females.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.